During the past decade, ZNA Jan Palfijn conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 13 clinical trials were completed, i.e. on average, 43.3% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 8 clinical trials were completed. i.e. 88.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ZNA Jan Palfijn" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ZNA Jan Palfijn" #1 collaborator was "Takeda" with 2 trials as a collaborator, "Agentschap voor Innovatie door Wetenschap en Technologie" with 1 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "Belgium Health Care Knowledge Centre" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "ZNA Jan Palfijn" are "Rheumatoid Arthritis" (10 trials), "Ulcerative Colitis" (4 trials), "Arthritis, Psoriatic" (3 trials), "Colitis, Ulcerative" (2 trials) and "Crohn Disease" (2 trials). Many other conditions were trialed in "ZNA Jan Palfijn" in a lesser frequency.

Most popular intervention types in "ZNA Jan Palfijn" are "Drug" (34 trials), "Other" (5 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Methotrexate" (4 trials), "Etrasimod" (3 trials), "Baricitinib" (2 trials) and "Dulaglutide" (2 trials). Other intervention names were less common.

The vast majority of trials in "ZNA Jan Palfijn" are 33 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "ZNA Jan Palfijn". undefined are not yet recruiting, 7 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in ZNA Jan Palfijn, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ZNA Jan Palfijn, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 1 trials that are defined as “Not Applicable".